FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2035366757> ?p ?o ?g. }

• W2035366757 endingPage "1136" @default.
• W2035366757 startingPage "1129" @default.
• W2035366757 abstract "In Brief OBJECTIVE: To evaluate whether 3-month administration of CDB-2914, a selective progesterone receptor modulator, reduces leiomyoma size and symptoms. METHODS: Premenopausal women with symptomatic uterine leiomyomata were randomly assigned to CDB-2914 at 10 mg (T1) or 20 mg (T2) daily or to placebo (PLC) for 3 cycles or 90–102 days if no menses occurred. The primary outcome was leiomyoma volume change determined by magnetic resonance imaging at study entry and within 2 weeks of hysterectomy. Secondary outcomes included the proportion of amenorrhea, change in hemoglobin and hematocrit, ovulation inhibition, and quality-of-life assessment. RESULTS: Twenty-two patients were allocated, and 18 completed the trial. Age and body mass index were similar among groups. Leiomyoma volume was significantly reduced with CDB-2914 administration (PLC 6%; CDB-2914 –29%; P=.01), decreasing 36% and 21% in the T1 and T2 groups, respectively. During treatment, hemoglobin was unchanged, and the median estradiol was greater than 50 pg/mL in all groups. CDB-2914 eliminated menstrual bleeding and inhibited ovulation (% ovulatory cycles: CDB-2914, 20%; PLC, 83%; P=.001). CDB-2914 improved the concern scores of the uterine leiomyoma symptom quality-of-life subscale (P=.04). One CDB-2914 woman developed endometrial cystic hyperplasia without evidence of atypia. No serious adverse events were reported. CONCLUSION: Compared with PLC, CDB-2914 significantly reduced leiomyoma volume after three cycles, or 90–102 days. CDB-2914 treatment resulted in improvements in the concern subscale of the Uterine Fibroid Symptom Quality of Life assessment. In this small study, CDB-2914 was well-tolerated without serious adverse events. Thus, there may be a role for CDB-2914 in the treatment of leiomyomata. Clinical Trial Registration: ClinicalTrials.gov,www.clinicaltrials.gov, NCT00290251 LEVEL OF EVIDENCE: I CDB-2914 reduced leiomyoma volume, induced amenorrhea, and thus may be an effective therapy for uterine leiomyomata." @default.
• W2035366757 created "2016-06-24" @default.
• W2035366757 creator A5033936594 @default.
• W2035366757 creator A5036349190 @default.
• W2035366757 creator A5037278202 @default.
• W2035366757 creator A5039278044 @default.
• W2035366757 creator A5043403667 @default.
• W2035366757 creator A5051950292 @default.
• W2035366757 creator A5070388711 @default.
• W2035366757 creator A5082089356 @default.
• W2035366757 date "2008-05-01" @default.
• W2035366757 modified "2023-09-25" @default.
• W2035366757 title "CDB-2914 for Uterine Leiomyomata Treatment" @default.
• W2035366757 cites W1984592479 @default.
• W2035366757 cites W1984901643 @default.
• W2035366757 cites W19931880 @default.
• W2035366757 cites W1994792570 @default.
• W2035366757 cites W2016301974 @default.
• W2035366757 cites W2038743660 @default.
• W2035366757 cites W2039633328 @default.
• W2035366757 cites W2050638567 @default.
• W2035366757 cites W2073500252 @default.
• W2035366757 cites W2084945576 @default.
• W2035366757 cites W2105882735 @default.
• W2035366757 cites W2147700987 @default.
• W2035366757 cites W2159982320 @default.
• W2035366757 cites W4235450498 @default.
• W2035366757 doi "https://doi.org/10.1097/aog.0b013e3181705d0e" @default.
• W2035366757 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2742990" @default.
• W2035366757 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18448745" @default.
• W2035366757 hasPublicationYear "2008" @default.
• W2035366757 type Work @default.
• W2035366757 sameAs 2035366757 @default.
• W2035366757 citedByCount "151" @default.
• W2035366757 countsByYear W20353667572012 @default.
• W2035366757 countsByYear W20353667572013 @default.
• W2035366757 countsByYear W20353667572014 @default.
• W2035366757 countsByYear W20353667572015 @default.
• W2035366757 countsByYear W20353667572016 @default.
• W2035366757 countsByYear W20353667572017 @default.
• W2035366757 countsByYear W20353667572018 @default.
• W2035366757 countsByYear W20353667572019 @default.
• W2035366757 countsByYear W20353667572020 @default.
• W2035366757 countsByYear W20353667572021 @default.
• W2035366757 countsByYear W20353667572022 @default.
• W2035366757 countsByYear W20353667572023 @default.
• W2035366757 crossrefType "journal-article" @default.
• W2035366757 hasAuthorship W2035366757A5033936594 @default.
• W2035366757 hasAuthorship W2035366757A5036349190 @default.
• W2035366757 hasAuthorship W2035366757A5037278202 @default.
• W2035366757 hasAuthorship W2035366757A5039278044 @default.
• W2035366757 hasAuthorship W2035366757A5043403667 @default.
• W2035366757 hasAuthorship W2035366757A5051950292 @default.
• W2035366757 hasAuthorship W2035366757A5070388711 @default.
• W2035366757 hasAuthorship W2035366757A5082089356 @default.
• W2035366757 hasBestOaLocation W20353667571 @default.
• W2035366757 hasConcept C126322002 @default.
• W2035366757 hasConcept C126894567 @default.
• W2035366757 hasConcept C141071460 @default.
• W2035366757 hasConcept C142724271 @default.
• W2035366757 hasConcept C159110408 @default.
• W2035366757 hasConcept C197934379 @default.
• W2035366757 hasConcept C204787440 @default.
• W2035366757 hasConcept C27081682 @default.
• W2035366757 hasConcept C2777795800 @default.
• W2035366757 hasConcept C2778058571 @default.
• W2035366757 hasConcept C2779234561 @default.
• W2035366757 hasConcept C2779494336 @default.
• W2035366757 hasConcept C2779951463 @default.
• W2035366757 hasConcept C2780566971 @default.
• W2035366757 hasConcept C29456083 @default.
• W2035366757 hasConcept C3017725331 @default.
• W2035366757 hasConcept C54355233 @default.
• W2035366757 hasConcept C71924100 @default.
• W2035366757 hasConcept C86803240 @default.
• W2035366757 hasConceptScore W2035366757C126322002 @default.
• W2035366757 hasConceptScore W2035366757C126894567 @default.
• W2035366757 hasConceptScore W2035366757C141071460 @default.
• W2035366757 hasConceptScore W2035366757C142724271 @default.
• W2035366757 hasConceptScore W2035366757C159110408 @default.
• W2035366757 hasConceptScore W2035366757C197934379 @default.
• W2035366757 hasConceptScore W2035366757C204787440 @default.
• W2035366757 hasConceptScore W2035366757C27081682 @default.
• W2035366757 hasConceptScore W2035366757C2777795800 @default.
• W2035366757 hasConceptScore W2035366757C2778058571 @default.
• W2035366757 hasConceptScore W2035366757C2779234561 @default.
• W2035366757 hasConceptScore W2035366757C2779494336 @default.
• W2035366757 hasConceptScore W2035366757C2779951463 @default.
• W2035366757 hasConceptScore W2035366757C2780566971 @default.
• W2035366757 hasConceptScore W2035366757C29456083 @default.
• W2035366757 hasConceptScore W2035366757C3017725331 @default.
• W2035366757 hasConceptScore W2035366757C54355233 @default.
• W2035366757 hasConceptScore W2035366757C71924100 @default.
• W2035366757 hasConceptScore W2035366757C86803240 @default.
• W2035366757 hasIssue "5" @default.
• W2035366757 hasLocation W20353667571 @default.
• W2035366757 hasLocation W20353667572 @default.
• W2035366757 hasLocation W20353667573 @default.

• next